All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @itsjohannanavarro on TikTok · 100s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @itsjohannanavarro's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Literally don't know what's going on, but oh my gosh, okay
  2. 0:04A little update with my trezap a tide so last night Tuesday would have been my third
  3. 0:14Dose I have friggin forgot it you guys I literally forgot it
  4. 0:18It's Wednesday morning now
  5. 0:21But since last night I have nonstop been so nauseous
  6. 0:27I'm kind of getting scared. I generally go on
  7. 0:31I'm not pregnant. I hopefully I'm not sure like if I even if I was it's a way too soon to even like
  8. 0:40No, so that's why I'm saying I'm not you know
  9. 0:43Could it be because I forgot my dose last night that the effects like weighing off and like that's making my body feel nauseous
  10. 0:51so I'm gonna help a girl out because oh
  11. 0:54My gosh, I'm literally gonna eat my breakfast and then put the third dose today
  12. 0:58So I am literally a few hours behind so put it on a 8 30 p.m. On a Tuesday. It's 10 a.m
  13. 1:07This Wednesday morning
  14. 1:08Just feel nauseous like I haven't felt nauseous with the trezap a tide and I think now that it's wearing off
  15. 1:14I am is that normal? Has anybody experienced that because I think that's what's happening to me and
  16. 1:19Oh, I didn't make my breakfast about the same time. It's like I literally can't click my breakfast. I'm getting
  17. 1:25Noshous
  18. 1:27If someone let me know if this has happened to you like would the trezap a tide or some a gluten effect goes down
  19. 1:33Do you feel nauseous or what's going on with me because I don't think I'm pregnant. I can't be I better not be

GLP-1 third doses after bariatric surgery: what the data says

ItsJohanna💕

TikTok creator

182.8K viewsWatch on TikTok

Quick answer

The creator is on tirzepatide, likely in an early titration phase given she references her 'third dose,' and experienced unexpected nausea approximately 13 hours after a missed injection. She self-managed by taking the delayed dose the following morning, which falls within the FDA's four-day missed-dose window for tirzepatide. Her symptoms may reflect transient GI sensitivity during early titration rather than a pharmacologically meaningful drop in drug levels, given tirzepatide's approximately five-day half-life.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 third doses after bariatric surgery: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

GLP-1 third doses after bariatric surgery: what the data says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 third doses after bariatric surgery: what the data says" from ItsJohanna💕. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is on tirzepatide, likely in an early titration phase given she references her 'third dose,' and experienced unexpected nausea approximately 13 hours after a missed injection.

The reason this review is not generic is the source wording and the canonical claim label "glp1 i need to take my 3rd dose asap wls wlscommunity wlsjourney." In this clip, the useful excerpt is: "Literally don't know what's going on, but oh my gosh, okay A little update with my trezap a tide so last night Tuesday would have been my third Dose I have friggin forgot it you guys I literally forgot it It's Wednesday morning now But..." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GLP-1 and GIP receptor agonists affect gastric motility significantly; a 2022 NEJM study by Frías et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is on tirzepatide, likely in an early titration phase given she references her 'third dose,' and experienced unexpected nausea approximately 13 hours after a missed injection.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is on tirzepatide, likely in an early titration phase given she references her 'third dose,' and experienced unexpected nausea approximately 13 hours after a missed injection. She self-managed by taking the delayed dose the following morning, which falls within the FDA's four-day missed-dose window for tirzepatide. Her symptoms may reflect transient GI sensitivity during early titration rather than a pharmacologically meaningful drop in drug levels, given tirzepatide's approximately five-day half-life.
  • Tirzepatide has an approximately five-day half-life, meaning a 13-hour missed dose is unlikely to cause a sharp pharmacological drop in drug levels or classic withdrawal symptoms.
  • GLP-1 and GIP receptor agonists affect gastric motility significantly; a 2022 NEJM study by Frías et al. confirmed tirzepatide slows gastric emptying in a dose-dependent manner, which could contribute to GI sensitivity during dose transitions.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Tirzepatide has an approximately five-day half-life, meaning a 13-hour missed dose is unlikely to cause a sharp pharmacological drop in drug levels or classic withdrawal symptoms.
  • GLP-1 and GIP receptor agonists affect gastric motility significantly; a 2022 NEJM study by Frías et al. confirmed tirzepatide slows gastric emptying in a dose-dependent manner, which could contribute to GI sensitivity during dose transitions.
  • FDA prescribing guidelines state tirzepatide can be taken within four days of a missed scheduled dose, so taking it the morning after is within the approved window.
  • Nausea during early tirzepatide titration is common and can be unpredictable; it does not always indicate a dose issue and should be reported to a prescriber if persistent or severe.
  • Tirzepatide is not approved for use during pregnancy, and animal studies show potential fetal harm. Any reproductive-age person on tirzepatide who suspects pregnancy should contact a clinician immediately, not dismiss it in a caption.
  • Self-managing missed doses based on social media comments rather than prescriber guidance increases the risk of errors, especially during early titration phases when the body is still adjusting to the medication.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @itsjohannanavarro actually say?

She noticed nausea the morning after missing her third tirzepatide dose and wondered aloud whether the drug "wearing off" could be causing her symptoms. Her words: "I think now that it's wearing off I am" feeling nauseous. She also briefly floated pregnancy as a possibility before dismissing it. Then she announced she'd take her missed dose about 13 hours late, first thing Wednesday morning.

This is a reasonable, genuine question from someone paying attention to her own body. She's not making wild claims, she's pattern-matching based on timing. That part is actually worth taking seriously. What she gets wrong is the pharmacology behind why it might be happening, and the decision to just take it the next morning without flagging it to a prescriber.

Does the science back this up?

Sort of, but not in the way she's framing it. Nausea from tirzepatide discontinuation or dose delays isn't well-documented as a formal withdrawal phenomenon, but there's a plausible mechanism worth understanding.

Tirzepatide works on both GIP and GLP-1 receptors, and GLP-1 receptor agonists are known to affect gastric emptying and gut motility significantly. A 2022 study by Frías et al. in The New England Journal of Medicine confirmed that tirzepatide slows gastric emptying in a dose-dependent way. When that slowing effect drops off, even temporarily, the gut may respond to a kind of motility rebound. This isn't the same as classic withdrawal, but it could explain why some people feel off when a dose is delayed.

There's also a simpler explanation: she may have just eaten something that didn't agree with her, or her baseline nausea sensitivity is reasserting itself now that the drug's appetite-suppressing, motility-altering effects are partially fading. Tirzepatide has a half-life of approximately five days, so 13 hours late is unlikely to cause a dramatic drop in drug levels. The more probable explanation is individual sensitivity, not pharmacological withdrawal.

What did they get wrong (or right)?

She got the instinct right: drug timing can affect how your body feels, and it's smart to connect symptoms to your medication schedule. That's good self-monitoring.

What she got wrong is the framing of "wearing off" as a rapid process. Tirzepatide's roughly five-day half-life means her drug levels at 13 hours post-missed-dose were not dramatically lower than usual. If she's feeling nauseous, it's more likely her body's baseline GI sensitivity reasserting itself, or a completely unrelated cause, than a pharmacokinetic cliff.

The other concern is her self-directed decision to just take the dose Wednesday morning with no mention of checking in with her prescriber. The FDA prescribing information for tirzepatide (Mounjaro/Zepbound) states that if a dose is missed, it can be administered within four days of the scheduled day. She was within that window, so the decision itself isn't dangerous, but defaulting to provider guidance rather than self-managing in a comments section is always the better move.

She also dismissed pregnancy a little too quickly given she's a reproductive-age woman on a medication not approved for use during pregnancy. That's worth a real conversation with a clinician, not a TikTok footnote.

What should you actually know?

Missing a single tirzepatide dose by 13 hours is unlikely to produce dramatic pharmacological withdrawal because the drug's half-life is long enough to buffer short delays. However, nausea can be unpredictable with GLP-1 and GIP receptor agonists, especially during the early titration phase when the body is still adjusting.

The FDA's official guidance on missed tirzepatide doses is clear: if you miss a dose and it's within four days of your scheduled injection day, take it as soon as you remember. If more than four days have passed, skip it and resume your regular schedule. Do not take two doses to make up for a missed one.

Persistent or unexpected nausea, especially nausea that's new and doesn't fit your usual pattern on the medication, is worth reporting to your prescriber. It could be the drug, it could be something else entirely, and only a provider who knows your full history can help you sort that out. Self-diagnosing in a TikTok video, even a thoughtful one, is not a substitute for that conversation.

  • Tirzepatide is not approved for use during pregnancy. Anyone on tirzepatide who is or may be pregnant should contact their prescriber immediately.
  • GI symptoms during dose transitions are common and not always a sign something is wrong, but they should be monitored.
  • The comments section of a WLS TikTok video is not a clinical consultation.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

ItsJohanna💕 · TikTok creator

182.8K views on this video

I need to take my 3rd dose ASAP. #wls #wlscommunity #wlsjourney #wlssupport #wlsstrong #wlsgoals #wlslife #Vsg #vsgcommunity #vsgjourney #vsgfamily #vsgsupport #vsgsurgery #vsglifestyle #bariatric #bariatricsurgery #bariatricsleeve #Bariatriccommunity #bariatriclife #bariatricos #mangagastrica #wlsmexico #vsgmexico #wlsfood #vsgfood #vsgpregnancy #glp1 #WLSpregnancy #glp1forweightloss #glp1medication #glp1community

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide has an approximately five-day half-life, meaning a 13-hour missed?

Tirzepatide has an approximately five-day half-life, meaning a 13-hour missed dose is unlikely to cause a sharp pharmacological drop in drug levels or classic withdrawal symptoms.

What does the video say about glp-1?

GLP-1 and GIP receptor agonists affect gastric motility significantly; a 2022 NEJM study by Frías et al. confirmed tirzepatide slows gastric emptying in a dose-dependent manner, which could contribute to GI sensitivity during dose transitions.

What does the video say about fda prescribing guidelines state tirzepatide can be taken within four?

FDA prescribing guidelines state tirzepatide can be taken within four days of a missed scheduled dose, so taking it the morning after is within the approved window.

What does the video say about nausea during early tirzepatide titration?

Nausea during early tirzepatide titration is common and can be unpredictable; it does not always indicate a dose issue and should be reported to a prescriber if persistent or severe.

What does the video say about tirzepatide?

Tirzepatide is not approved for use during pregnancy, and animal studies show potential fetal harm. Any reproductive-age person on tirzepatide who suspects pregnancy should contact a clinician immediately, not dismiss it in a caption.

What does the video say about self-managing missed doses based on social media comments rather than?

Self-managing missed doses based on social media comments rather than prescriber guidance increases the risk of errors, especially during early titration phases when the body is still adjusting to the medication.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ItsJohanna💕, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.